Cholangiocarcinoma · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes cholangiocarcinoma compared with placebo (very low certainty).
1 finding from 1 review
Colorectal cancer · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes mortality (All‐cause) compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Hepatorenal syndrome (Number of participants who did not achieve reversal of hepatorenal syndrome) · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes hepatorenal syndrome (Number of participants who did not achieve… compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.79 [0.63, 0.99]
394 participants
Very low
Serious adverse events · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes serious adverse events compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Non‐serious adverse events: diarrhoea or abdominal pain, or both · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes non‐serious adverse events: diarrhoea or abdominal pain, or both compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 3.5 [1.19, 10.27]
221 participants
Very low
All‐cause mortality · hospitalised adults at nutritional risk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
‐ at end of intervention · hospitalised adults at nutritional risk
Nutrition support showed no clear difference in ‐ at end of intervention compared with no intervention, placebo, or treatment (low certainty).
1 finding from 1 review
at maximum · hospitalised adults at nutritional risk
Nutrition support may leads to lower ‐ at maximum compared with no intervention, placebo, or treatment (low certainty).
3 findings from 1 review
RR 0.93 [0.88, 0.99]
127 studies · 23170 participants
Low
RR 0.91 [0.85, 0.97]
137 studies · 23413 participants
Low
no estimate extracted
2 studies · 3961 participants
Very low
Serious adverse events · hospitalised adults at nutritional risk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
‐at end of intervention · hospitalised adults at nutritional risk
1 finding from 1 review
Weight (kg) · hospitalised adults at nutritional risk
1 finding from 1 review
Intervention not reported
Interventions · people undergoing liver transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Tacrolimus plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Tacrolimus plus mycophenolate plus glucocorticosteroids · people undergoing liver transplantation
It is very uncertain whether the intervention changes tacrolimus plus mycophenolate plus glucocorticosteroids (very low certainty).
1 finding from 1 review
Intervention not reported
Tacrolimus plus sirolimus · people undergoing liver transplantation
The intervention may leads to higher tacrolimus plus sirolimus (low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A · people undergoing liver transplantation
It is very uncertain whether the intervention changes cyclosporine A (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A plus azathioprine · people undergoing liver transplantation
It is very uncertain whether the intervention changes cyclosporine A plus azathioprine (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A plus azathioprine plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Cyclosporine A plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low